^
    Back
    Association details:
    Biomarker:NF2 mutation
    Cancer:Kidney Medullary Carcinoma
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor) +
    erlotinib (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Cancers (Basel)
    Title:

    Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma

    Published date:
    04/30/2021
    Excerpt:
    The one patient (BE6) harboring a truncating NF2 mutation achieved SD as best response with a PFS of 4.2 months and an OS1 of 22.3 months following bevacizumab plus erlotinib initiation….bevacizumab plus erlotinib showed promising clinical activity and was well tolerated in heavily pre-treated patients with RMC
    DOI:
    10.3390/cancers13092170